Biofrontera AG announced that it has established a subsidiary to continue the commercialization of Ameluz® in the United Kingdom. The newly founded Biofrontera UK Ltd. Is based in Cambridge, UK and headed by Ms. Pilar de la Huerta and Dr. Montserrat Foguet as Managing Directors.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.35 EUR | -.--% | +1.16% | -12.72% |
Apr. 30 | Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 11 | Biofrontera Files Prospectus for Potential Secondary Stock Offerings | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-12.72% | 23.88M | |
+34.00% | 704B | |
+26.10% | 577B | |
-7.75% | 348B | |
+18.53% | 327B | |
+4.95% | 288B | |
+15.13% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-4.89% | 147B |
- Stock Market
- Equities
- B8F Stock
- News Biofrontera AG
- Biofrontera AG Announces Executive Appointments to Biofrontera UK Ltd